recentpopularlog in

jerryking : vas_narasimhan   2

Vas Narasimhan of Novartis: ‘We Are Not at All Prepared for a Pandemic’ - The New York Times
How do you deal with all these stressors?

I’ve been working with a coach on four principles: mind-set, movement, nutrition and recovery. On mind-set, I set intentions every day. I find that trying to be clear about what I want to accomplish in the day, right in the morning, is very important. What’s the impact I want to have?

Nutrition is, Am I eating for performance, or am I eating to enjoy? I’m convinced that your glycemic status impacts your overall ability to make good decisions, handle stress, all of those things.

Movement: I’m a Peloton addict.

And then recovery. I try to sleep seven or eight hours a night. I take all my vacations with my family. I go on walks with my wife, who’s like my life coach, and professional coach, and all of everything in between.
CEOs  glycemic_index  intentionality  pandemics  Novartis  Vas_Narasimhan 
6 weeks ago by jerryking
Novartis’s new chief sets sights on ‘productivity revolution’
SEPTEMBER 25, 2017 | Financial Times | Sarah Neville and Ralph Atkins.

The incoming chief executive of Novartis, Vas Narasimhan, has vowed to slash drug development costs, eyeing savings of up to 25 per cent on multibillion-dollar clinical trials as part of a “productivity revolution” at the Swiss drugmaker.

The time and cost of taking a medicine from discovery to market has long been seen as the biggest drag on the pharmaceutical industry’s performance, with the process typically taking up to 14 years and costing at least $2.5bn.

In his first interview as CEO-designate, Dr Narasimhan says analysts have estimated between 10 and 25 per cent could be cut from the cost of trials if digital technology were used to carry them out more efficiently. The company has 200 drug development projects under way and is running 500 trials, so “that will have a big effect if we can do it at scale”.......Dr Narasimhan plans to partner with, or acquire, artificial intelligence and data analytics companies, to supplement Novartis’s strong but “scattered” data science capability.....“I really think of our future as a medicines and data science company, centred on innovation and access.”

He must now decide where Novartis has the capability “to really create unique value . . . and where is the adjacency too far?”.....Does he need the cash pile that would be generated by selling off these parts of the business to realise his big data vision? He says: “Right now, on data science, I feel like it’s much more about building a culture and a talent base . . . ...Novartis has “a huge database of prior clinical trials and we know exactly where we have been successful in terms of centres around the world recruiting certain types of patients, and we’re able to now use advanced analytics to help us better predict where to go . . . to find specific types of patients.

“We’re finding that we’re able to significantly reduce the amount of time that it takes to execute a clinical trial and that’s huge . . . You could take huge cost out.”...Dr Narasimhan cites one inspiration as a visit to Disney World with his young children where he saw how efficiently people were moved around the park, constantly monitored by “an army of [Massachusetts Institute of Technology-]trained data scientists”.
He has now harnessed similar technology to overhaul the way Novartis conducts its global drug trials. His clinical operations teams no longer rely on Excel spreadsheets and PowerPoint slides, but instead “bring up a screen that has a predictive algorithm that in real time is recalculating what is the likelihood our trials enrol, what is the quality of our clinical trials”.

“For our industry I think this is pretty far ahead,” he adds.

More broadly, he is realistic about the likely attrition rate. “We will fail at many of these experiments, but if we hit on a couple of big ones that are transformative, I think you can see a step change in productivity.”
adjacencies  algorithms  analytics  artificial_intelligence  attrition_rates  CEOs  data_driven  data_scientists  drug_development  failure  Indian-Americans  kill_rates  massive_data_sets  multiple_targets  Novartis  pharmaceutical_industry  predictive_analytics  productivity  productivity_payoffs  product_development  real-time  scaling  spreadsheets  Vas_Narasimhan 
november 2017 by jerryking

Copy this bookmark:





to read